Expert Review of Hematology最新文献_第2页

Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches. 改进套细胞淋巴瘤的风险分层：整合新的联合治疗和个性化方法。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-08-10 DOI: 10.1080/17474086.2026.2715445

Alessia Moioli, Enrico Carazzai, Ilaria Mion, Matilde Paluzzi, Maria Elena Carazzolo, Francesca Maria Quaglia, Carlo Visco

{"title":"Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.","authors":"Alessia Moioli, Enrico Carazzai, Ilaria Mion, Matilde Paluzzi, Maria Elena Carazzolo, Francesca Maria Quaglia, Carlo Visco","doi":"10.1080/17474086.2026.2715445","DOIUrl":"10.1080/17474086.2026.2715445","url":null,"abstract":"Introduction: Mantle cell lymphoma is a biologically heterogeneous B-cell lymphoma characterized by highly variable clinical outcomes. This review discusses the evolution of risk stratification and emerging treatment approaches, highlighting the need for personalized and risk-adapted treatment strategies.Areas covered: This review examines the evolution of risk stratification in mantle cell lymphoma, from clinical prognostic models to molecular and dynamic biomarkers, such as TP53 mutation, genomic profiling, minimal residual disease, and circulating tumor DNA. Emerging therapeutic approaches, including targeted combinations, chemotherapy-free regimens, cellular immunotherapy, and minimal residual disease-driven strategies, are critically reviewed. The literature search was conducted using PubMed (MEDLINE) and updated through June 2026.Expert opinion: Risk stratification is increasingly shifting from traditional clinical models toward integrated biological and genomic models that better capture disease heterogeneity and support personalized and risk‑adapted treatment. Emerging evidence supports novel chemo-free targeted combinations, particularly for high-risk patients while further research is needed to refine treatment selection and identify additional determinants of prognosis and treatment resistance in lower‑risk disease.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1159-1168"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effective treatment with preventing skeletal-related event development in multiple myeloma patients. 预防多发性骨髓瘤患者骨骼相关事件发展的有效治疗。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-07-24 DOI: 10.1080/17474086.2026.2708711

Nicola Giuliani, Matteo Scita, Anna Benedetta Dalla Palma, Laura Notarfranchi, Nicolas Thomas Iannozzi

{"title":"Effective treatment with preventing skeletal-related event development in multiple myeloma patients.","authors":"Nicola Giuliani, Matteo Scita, Anna Benedetta Dalla Palma, Laura Notarfranchi, Nicolas Thomas Iannozzi","doi":"10.1080/17474086.2026.2708711","DOIUrl":"10.1080/17474086.2026.2708711","url":null,"abstract":"Introduction: Osteolytic bone disease is the hallmark of multiple myeloma (MM) patients caused by an excessive osteoclast activation and impaired osteoblast function. It occurs in up to 80-90% of patients at the diagnosis or during the disease. Osteolytic lesions lead to skeletal-related events (SREs) such as pathological fractures, severe bone pain or spinal cord compression. Consequently, SREs are associated with reduced quality of life and potentially decreased survival.Areas covered: Bone-targeted therapy with bisphosphonates (BPs) including zoledronic acid or pamidronate has long been the standard of care, showing a significant effect on the prevention of the SREs; however, renal toxicity may limit their use. Denosumab, a monoclonal antibody anti-RANKL has been approved for the treatment of bone disease also in patients with renal insufficiency. The efficacy and the possible toxic effects of these drugs are discussed in this review balancing effective treatment with preventing SREs development in MM patients.Expert opinion: Bone modifying agents (BMAs) including BPs and denosumab are effective in the prevention of SREs in MM patients. Overall, these drugs are manageable with a low incidence of side effects. The effect of BMAs on MM patient survival in the era of the new drugs is still debated.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1169-1177"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of liver stiffness assessed by transient elastography in transfusion-dependent thalassemia. 输血依赖型地中海贫血患者瞬时弹性图评估肝脏硬度的决定因素。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-08-10 DOI: 10.1080/17474086.2026.2715465

Antonella Meloni, Paolo Ricchi, Laura Pistoia, Filomena Longo, Maria Caterina Putti, Anna Spasiano, Vincenza Rossi, Alberto Cossu, Priscilla Fina, Giuseppe Peritore, Vincenzo Positano, Andrea Barison

{"title":"Determinants of liver stiffness assessed by transient elastography in transfusion-dependent thalassemia.","authors":"Antonella Meloni, Paolo Ricchi, Laura Pistoia, Filomena Longo, Maria Caterina Putti, Anna Spasiano, Vincenza Rossi, Alberto Cossu, Priscilla Fina, Giuseppe Peritore, Vincenzo Positano, Andrea Barison","doi":"10.1080/17474086.2026.2715465","DOIUrl":"10.1080/17474086.2026.2715465","url":null,"abstract":"Background: Liver stiffness measurement (LSM) assessed by transient elastography (TE) is a validated noninvasive tool for staging liver fibrosis. This cross-sectional study investigated the determinants of LSM in a well-managed cohort of patients with transfusion-dependent β-thalassemia (TDT).Research design and methods: We included 163 TDT patients (42.06 ± 9.07 years; 46% females) enrolled in the Extension-Myocardial Iron Overload Network. All participants underwent magnetic resonance imaging (MRI) for iron quantification within three months of TE. Endocrine complications were defined according to established clinical criteria.Results: Mean LSM was 6.78 ± 3.49kPa, and advanced fibrosis (LSM ≥8kPa) was identified in 23.3% of patients. LSMs were significantly higher in patients with chronic hepatitis C virus (HCV) infection compared with those who were never infected or had cleared HCV, and in patients with at least one endocrinopathy compared with those without. LSMs correlated positively with body mass index and with mean serum levels of ferritin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT). No association was observed between LSM and MRI-derived liver iron concentration. Multivariate regression analysis identified chronic HCV infection, AST, and GGT as independent predictors of LSM.Conclusions: Chronic HCV infection and markers of hepatocellular injury were the main determinants of liver stiffness, underscoring the multifactorial nature of liver fibrosis in TDT.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1195-1203"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can artificial intelligence lead the next frontier of hemophilia management and care? 人工智能能否引领血友病管理和护理的下一个前沿？

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-07-28 DOI: 10.1080/17474086.2026.2708713

M Joseph John, Prantar Chakrabarti, Uday Yanamandra

引用次数: 0

Addressing the slow uptake of gene therapy for sickle cell disease: a lack of interest, a high cost, or a more complex issue? 解决镰状细胞病基因治疗的缓慢接受：缺乏兴趣，高成本，还是一个更复杂的问题？

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-10-01 Epub Date: 2026-07-31 DOI: 10.1080/17474086.2026.2711730

Lakshmanan Krishnamurti, Aishwarya Aiyer, Karthik Rayapureddi

{"title":"Addressing the slow uptake of gene therapy for sickle cell disease: a lack of interest, a high cost, or a more complex issue?","authors":"Lakshmanan Krishnamurti, Aishwarya Aiyer, Karthik Rayapureddi","doi":"10.1080/17474086.2026.2711730","DOIUrl":"10.1080/17474086.2026.2711730","url":null,"abstract":"Introduction: The approval of Gene Therapy (GT) for sickle cell disease (SCD) marks a major milestone in hematology, offering curative potential for SCD without the need for a allogeneic transplantation. Yet early real-world uptake has been slow. This delay in integration is likely due to complex intertwined barriers that require further elucidation.Areas covered: We conducted a structured review of the literature, searching PubMed/MEDLINE, Embase, and ClinicalTrials.gov through April 2026 for evidence on the economic, institutional, clinician-level, and patient-level barriers limiting adoption of GT for SCD, as well as global disparities in access.Expert opinion: Slow uptake of GT reflects the expected challenge of introducing a complex, resource-intensive intervention into a fragmented care system for an underserved population with a chronic debilitating illness. Addressing these barriers requires coordinated efforts from payers, institutions, clinicians, and patient communities. Without deliberate structural reform, GT risks widening existing health disparities rather than alleviating them.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1147-1158"},"PeriodicalIF":2.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148648433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rising myeloproliferative neoplasms in younger patients: preserving future fertility and pregnancies. 年轻患者骨髓增生性肿瘤的增加：保护未来的生育能力和妊娠。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-09-29 DOI: 10.1080/17474086.2026.2740886

Katarzyna Siekaniec, Marta Sobas

引用次数: 0

Implementation barriers of standardizing flow cytometric immune reconstitution monitoring post-allogeneic hematopoietic cell transplantation. 异基因造血细胞移植后流式细胞术免疫重建监测标准化的实施障碍。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-09-15 DOI: 10.1080/17474086.2026.2732991

Silvia Nucera, Giuseppe Gaipa, Chiara Buracchi

{"title":"Implementation barriers of standardizing flow cytometric immune reconstitution monitoring post-allogeneic hematopoietic cell transplantation.","authors":"Silvia Nucera, Giuseppe Gaipa, Chiara Buracchi","doi":"10.1080/17474086.2026.2732991","DOIUrl":"10.1080/17474086.2026.2732991","url":null,"abstract":"Introduction: Immune reconstitution (IR) after hematopoietic cell transplant (HCT) impacts patients' outcomes. However, assessment of IR is highly heterogeneous, affecting the possibility of producing solid evidence and hampering the potential use of IR as a clinical endpoint. Inter-center standardization of IR monitoring is therefore essential to advance the field and ultimately improve patient outcomes. While standardization in flow cytometry is feasible, it requires coordinated efforts across centers, including harmonization of pre-analytical variables (e.g. sample collection and handling) and analytical procedures.Areas covered: We review and discuss which steps should be taken to achieve standardization, from sample management to analytical process. The literature search was conducted using PubMed and updated through June 2026, with a preferential selection for international collaborative works.Expert opinion: The lesson learned from international consortia that have been working on standardization in flow cytometry should be directly applied to IR monitoring. This would require international collaborative efforts that could be achieved through existing working groups. Furthermore, in a time when artificial intelligence is gaining more space in medicine, a standardized approach would imply a dramatic increase in biological knowledge that can be derived from post-HCT IR, and this would translate into a clinical benefit for the patients.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-6"},"PeriodicalIF":2.8,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval. 自FDA批准以来，帕西替尼用于骨髓纤维化和血小板减少症的适应性。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-09-15 DOI: 10.1080/17474086.2026.2732995

Valentina Ardila, Sangeetha Venugopal

引用次数: 0

Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia. 急性髓性白血病menin抑制剂失效后的耐药机制和治疗策略。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-09-14 DOI: 10.1080/17474086.2026.2732994

Abdulrahman Alhajahjeh, Maximilian Stahl, Amer M Zeidan, Jan Philipp Bewersdorf

{"title":"Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia.","authors":"Abdulrahman Alhajahjeh, Maximilian Stahl, Amer M Zeidan, Jan Philipp Bewersdorf","doi":"10.1080/17474086.2026.2732994","DOIUrl":"10.1080/17474086.2026.2732994","url":null,"abstract":"Introduction: Menin inhibitors, including the FDA-approved agents revumenib and ziftomenib, have emerged as transformative targeted therapies in acute myeloid leukemia (AML), particularly in KMT2A-rearranged (KMT2Ar) and NPM1-mutated (NPM1m) disease. Despite high initial response rates, durability remains limited, and most patients relapse within months, defining a critical unmet clinical need.Areas covered: This review synthesizes current evidence on the biological and clinical landscape of menin inhibitor resistance in AML. We address on-target MEN1 mutations, off-target clonal evolution, epigenetic and transcriptional reprogramming, and microenvironment-mediated adaptive signals. We also review clinical outcomes after treatment failure and emerging therapeutic strategies. A literature search was conducted in PubMed and ClinicalTrials.gov through June 2026, supplemented by recent international congress abstracts.Expert opinion: No clinical tests are currently available to reliably predict emerging resistance or early therapeutic failure, and treatment options after menin inhibitor failure remain limited and largely empiric, including, if not previously used, venetoclax-based regimens, mutation-directed therapies, and intensive chemotherapy as a bridge to allogeneic HSCT. Emerging preclinical data identify key vulnerabilities, including bypass signaling, apoptotic dependence, and epigenetic escape, providing a rationale for next-generation combination strategies, ideally in the frontline setting to maximize the chance of success and minimize the risk of clonal escape.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-16"},"PeriodicalIF":2.8,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing thrombotic risk in myeloproliferative disorders. 管理骨髓增生性疾病的血栓形成风险。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-09-12 DOI: 10.1080/17474086.2026.2732981

Gerard Gurumurthy, Minji Ho, Jecko Thachil, Priya Sriskandarajah

{"title":"Managing thrombotic risk in myeloproliferative disorders.","authors":"Gerard Gurumurthy, Minji Ho, Jecko Thachil, Priya Sriskandarajah","doi":"10.1080/17474086.2026.2732981","DOIUrl":"https://doi.org/10.1080/17474086.2026.2732981","url":null,"abstract":"Introduction: Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders associated with arterial and venous thrombosis. Thrombotic risk reflects conventional vascular factors and disease-specific thromboinflammatory biology. Thrombosis remains a major cause of morbidity and mortality in MPNs despite contemporary guidelines. Thus, there remains a challenging therapeutic uncertainty across diverse clinical presentations.Areas covered: We reviewed PubMed-listed articles on the epidemiology, mechanisms, risk stratification and clinical management of thrombosis in classical Philadelphia-negative MPNs. We discuss evidence for aspirin, hematocrit control, cytoreduction and anticoagulation choice. We also examine management in special populations such as in pregnancy and frailty. Lastly, we give an overview on the emerging use of Direct oral anticoagulants (DOACs) in unusual site thrombosis in this setting.Expert opinion: Thrombosis in MPNs should not be treated as a single entity. Arterial, venous and unusual-site events all differ in biology and this can have therapeutic implications. Future progress requires personalized strategies that balance thrombosis prevention, bleeding risk and clonal disease control in a heterogenous group.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-12"},"PeriodicalIF":2.8,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148944683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0